Prognostic significance of peritoneal metastasis from colorectal cancer treated with first-line triplet chemotherapy

Table 2 Univariate analysis of progression-free survival and overall survival in 51 patients with metastatic colorectal cancer treated with triplet therapy

	PFS		OS
	Mo (95% CI)	P value	Mo (95% CI)	P value
Age		0.034		0.157
< 65	12.4 (5-19.9)		31.3 (14.9-47.6)
≥ 65	5.7 (5-6.3)		20.9 (0-45.2)
Gender		0.429		0.439
Male	10.8 (4.3-17.3)		31.3 (13.2-49.3)
Female	9.4 (0-19.3)		29.1 (0-58.5)
Site of primary		0.823		0.844
Left	10.8 (4.1-17.5)		31.3 (14.8-47.7)
Right	9.1 (0.5-17.8)		20.9 (0-82.8)
Performance status		0.068		0.532
0-1	15.9 (7-24.8)		38.2 (22.9-53.5)
2	6.9 (2.8-11)		31.3 (5.7-56.8)
Liver metastasis		0.046		0.001
Yes	8.9 (7-10.9)		24.7 (10.9-38.5)
No	15.9 (5.7-26.1)		NR
Lung metastasis		0.011		0.087
Yes	8.9 (6.4-11.4)		24.7 (17.6-31.9)
No	13.7 (5.8-21.6)		40 (0-84.7)
Peritoneum metastasis		0.401		0.368
Yes	9.4 (8.6-10.1)		NR
No	13.7 (4.4-22.9)		31.3 (19.5-43.1)
KRAS		0.957		0.851
Wild	13.7 (0-30.7)		38.2 (23.3-53)
Mutant	10.8 (5.2-16.4)		29.1 (20.8-37.3)
Unknown	9.4 (8.2-10.5)		22.1 (0-44.4)
Prior surgery to primary		0.928		0.764
Yes	10.8 (3-18.6)		29.1 (23.7-34.4)
No	10.2 (3.4-17)		40 (14.8-65.2)
No of metastatic sites		0.565		0.278
1	12.4 (6.7-18.2)		61.7 (0-127.7)
> 1	8.9 (6.6-11.3)		27.6 (21.9-33.4)
Metastasectomy		0.001		0.002
Yes	18.6 (0-NR)		NR
No	8 (5.4-10.6)		27.6 (20.8-34.4)

PFS: Progression-free survival; OS: Overall survival; CI: Confidence interval; NR: Not reached.